International leader with more than 30 years of experience in the pharma industry, including 20 years as CEO in life science companies such as AstraZeneca Hungary, Schering-Plough and Organon Biosciences Sweden, AutomationsPartner Sweden and Fürst Medicinskt Laboratorium Filial Sweden. Extensive industrial and technical knowledge in diagnostics, automation, digital pathology, global marketing, acquisitions, organic growth and implementation of efficiency measures. Other ongoing assignments: COO Scandinavian ChemoTech AB (publ). Number of shares: 0 Number of warrants: 0 Dependent of company, independent of larger shareholders.
Read MoreArchives: Board Member
Post type for Board Member
Ingrid Hultgren
Ingrid Hultgren holds a degree in microbiology from Uppsala University and has almost 40 years of experience in life science. Within in vitro diagnostics, she has worked with bacterial and viral diagnostics development as well as instrument and reagent development, including antibody-based reagents, at Pharmacia Diagnostics. In medical technology she has worked at Arjo AB (publ) with product development, documentation systems, quality management, and process control of CAPA (corrective and preventive action) and deviation management. She has previously been a board member of Arjo AB (publ) and Svenskt Projektforum. Number of shares: 25,000 Independent of the company's major shareholders, the…
Read MoreRoland Andersson
Professor of surgery at Lund University since 2000. Solid clinical experience and clinical and transitional research. Author of more than 500 articles in peer-reviewed journals. Supervisor for about 30 completed graduate students in the areas of cancer, systematic inflammation, organ failure and bowel function. Other ongoing assignments: Professor of surgery, Lund University. CEO and board member of Foresight Pharma AB. Chairman of the Board of Reccan Diagnostics AB. Board member at Nordic Biotechnology AB, Aqilion AB and Nordic Oncology in Lund AB. Number of shares: 100,000 Number of TO4: 95,000 Independent of company, independent of larger shareholders.
Read MoreUlf Bladin
Medical candidate from Karolinska Institutet, B.Sc. and Master from Stockholm School of Economics. Currently CEO of Prolight Diagnostics. Has previously been, among other things, General Manager, Vice President of EMEA Region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, Vice President with global responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia AB. Ulf Bladin has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme. Other ongoing assignments: CEO and board member of Prolight Diagnostics AB (publ.), board member of SpectraCure AB (publ), SPCIN AB and UB…
Read MoreStefan Andersson-Engels
Professor of physics at Lund University until 2016. Since 2016 director of Biophotonics at Tyndall National Institute, Ireland. Postdoc at McMasters University in Hamilton, Ontario, Canada. Received Erna Ebeling's award, Swedish Society for Medical Technology and Physics, 2003. First-time candidate for the appointment of the biomedical physics professor at the Royal Institute of Technology, Stockholm 1996. Co-author of more than 200 articles in peer-reviewed journals. Other ongoing assignments: Director of Biophotonics at Tyndall National Institute, Ireland. Chairman of the Board of NanoEcho AB (publ). Share of shares privately and through related parties: 2,100,000 Number of warrants: 0 Dependent in relation to…
Read More